USFDA recognized Antrodia cinnamomea mycelia (NDIN No.1170)
TAIPEI, May 20, 2021 - (ACN Newswire via SEAPRWire.com) - The history of Antrodia cinnamomea consumption by indigenous tribes in Taiwan dates back two hundred years ago, while people in the Western world know little about this ingredient. The USFDA NDI acknowledgement without objection to Greenyn's Antromax was the 1st notification after numerous attempts in the past 14 years. We are honored to establish a stepping-stone for the A. cinnamomea to the US health markets estimated at 10 billion US dollars.Dr. Kao Shung-te (middle) of China Medical University Hospital and Dr. Houng Jer-yiing (left) of I-Shou University Medical School presented the study results of the randomized double-blind clinical trial and the bioavailability of Antromax in different dosages forms, respectively.Antromax(R)– dripping pills, mycelia powder, emulsion powder (left to right).Manufacturing site of Greenyn Biotechnology in TaichungHealth food of Antromax(R) in livercare in Taiwan (left) and Antromax(R) complex beverage (right).USFDA acknowledged Antrodia cinnamomea as new dietary ingredientsOn April 12th, Greenyn Biotechnology Corporation hosted a seminar - "The international development of Taiwan's Antrod...
